Physician profile
Richard C Dodd
NPI 1427110378
$526,035.83
in general payments reported to CMS, 2019-2025
38 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163K · 2020: $48K · 2021: $92K · 2022: $132K · 2023: $57K · 2024: $12K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Food and Beverage: $3,251 · Consulting Fee: $1,312 · Travel and Lodging: $1,032 · Education: $10.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85,796.25 |
| Food and Beverage | $3,250.97 |
| Consulting Fee | $1,311.96 |
| Travel and Lodging | $1,031.79 |
| Education | $10.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $155,001.66 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $101,673.29 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $67,208.44 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $66,820.83 | 2019-2025 | Nexium, Airsupra, Breztri |
| Lilly USA, LLC | $63,010.51 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60,156.82 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Tandem Diabetes Care, INC. | $6,271.26 | 2019-2020 | |
| Esperion Therapeutics, INC. | $3,082.36 | 2020-2025 | Nexletol |
| Medtronic, INC. | $438.92 | 2021-2023 | Minimed 780g |
| Novo Nordisk INC | $360.44 | 2023-2025 | Ozempic, Rybelsus |
| Amgen INC. | $262.81 | 2019-2025 | Evenity, Prolia, Repatha |
| Insulet Corporation | $244.53 | 2021-2025 | Omnipod |
| Abbvie INC. | $212.05 | 2020-2025 | Vraylar, Ubrelvy |
| Dexcom, INC. | $208.89 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $180.71 | 2019-2023 | Freestyle Libre 3 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.